Harmony Biosciences (HRMY) Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HRMY shares.
View HRMY analyst ratings or view top-rated stocks.

9 brokers have issued 1 year price targets for Harmony Biosciences' stock. Their HRMY share price forecasts range from $43.00 to $75.00. On average, they expect the company's stock price to reach $62.89 in the next year. This suggests a possible upside of 74.7% from the stock's current price.
View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts.

Harmony Biosciences' stock was trading at $55.10 at the start of the year. Since then, HRMY shares have decreased by 34.7% and is now trading at $35.99.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our HRMY earnings forecast.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) posted its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.04. The firm had revenue of $119.13 million for the quarter, compared to analyst estimates of $118.21 million. Harmony Biosciences had a net margin of 40.19% and a trailing twelve-month return on equity of 49.67%.

ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco S&P SmallCap Quality ETF (XSHQ) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).

(HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO.

Harmony Biosciences trades on the NASDAQ under the ticker symbol "HRMY."

Harmony Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (9.33%), BlackRock Inc. (8.27%), State Street Corp (1.74%), Dimensional Fund Advisors LP (1.39%), Macquarie Group Ltd. (1.38%) and Macquarie Group Ltd. (1.38%). Insiders that own company stock include Andreas Wicki, Holdings A/S Novo, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs.
View institutional ownership trends.

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HRMY stock can currently be purchased for approximately $35.99.

Harmony Biosciences (NASDAQ:HRMY) has a market capitalization of $2.16 billion and generates $437.86 million in revenue each year. The company earns $181.47 million in net income (profit) each year or $3.10 on an earnings per share basis.

The company employs 180 workers across the globe.

Harmony Biosciences' mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The official website for the company is www.harmonybiosciences.com. The company can be reached via phone at 484-539-9800 or via email at lcaperelli@harmonybiosciences.com.